If a thread on Reddit is to be believed, one telehealth platform out there is using a contract pharmacy that is inserting Otter Pops as ice packs in the compounded GLP-1 drugs they are dispensing.
If APC had a tattoo on its bicep — if we had a bicep, I mean — it might well read “Consult legal counsel.”
APC sent a letter to the New Mexico Board of Pharmacy this week commenting on its proposed amendments that would align the state with USP (good), but would also require that pharmacists ensure all flavors are inert (yikes).
The APC Board of Directors has voted to name Gina Besteman (previously vice president) the board chair-elect after the resignation of Michelle Moser from the position. Besteman will assume the chair in January 2025.
Earlier this week APC received a letter from the FDA explaining the agency's concerns regarding dosing and patient usage of compounded semaglutide and tirzepatide.
If you haven’t already, don’t forget to download and share the 2023-2024 edition of our Snapshot of Pharmacy Compounding in America.
On Tuesday, the Federal Trade Commission released a scathing, two-years-in-the-making report about PBMs.
Several members have contacted us about a story that ran on NPR’s Morning Edition about a pharmacy in Texas that compounded the chemical used for lethal injections.
We’ve been bugging the California Board of Pharmacy (politely!) for a while, trying to get a statement on its position and enforcement posture regarding the compounding of FDA-approved drugs that are currently in shortage.
The Mamas and the Papas said you can’t trust Mondays, but that’s not always true. You can count on two things happening today, July 15. Whether you take advantage of them is up to you — but I hope you do.
APC has just released the 2023–2024 edition of our Compounding Pharmacy Snapshot — a slick overview of the practice of pharmacy compounding in the US of A.
Take our July 15 session (really, you should take it) where APC’s Tenille Davis is covering two of today’s critical topics: Best practices in both ketamine and GLP-1 compounding.
Registration is open for Compounders on Capitol Hill! If you’re planning to attend, the sooner you register the better because we’re starting to schedule visits with legislators, and we want to be sure you’re included.
APC CEO Scott Brunner and PCCA’s A.J. Day attended a forum in Washington, D.C., on the emergence of ketamine as an area of therapeutic interest.
APC is always keeping track of what state boards of pharmacy are up to, and we’ll reach out when we think something needs clarification. Here’s a sampling of the kind of letters we’ve sent recently.
We blasted through our expectations for our virtual town hall on compounding semaglutide on June 26, with almost 700 people registered.
APC briefed about four dozen House of Representatives healthcare staffers on the practice of pharmacy compounding — and cleared some of the muddied waters.
We learned this week that several compounding pharmacies have received a cease-and-desist letter from a law firm representing Eli Lilly.
Demonstrate your commitment to your patients and practice at APC’s annual DC fly-in for pharmacy compounders, September 17-18 at Hilton National Mall.
The FDA is proposing a rule that would add categories to both the 503A and 503B demonstrably difficult to compound (DDC) lists — a plan that has a host of issues.
The California Board of Pharmacy has proposed several new regulations for pharmacy compounding, some of which, to put it bluntly (and we did put it bluntly), are not rooted in science or evidence.
Well check this out: A news story about compounded GLP-1s that’s actually accurate, sans all the usual hand-wringing and fear-mongering.
Okay, not quite the cover, but APC has certainly been quoted in that and dozens of other publications over the past several months as the GLP-1 phenomenon has shone a bright light on pharmacy compounding.
Learn what’s at stake and what APC is doing about it — and how you can help … even if you don’t compound GLP-1s.
The FDA held a listening session on the "Use and Processes of Advisory Committees" on Thursday. APC's Tenille Davis and PCCA's AJ Day were there.
In comments submitted earlier this week, APC took issue with provisions of proposed new compounding regulations from the California Board of Pharmacy.
APC will be in Tampa next Wednesday, June 12 for a CompoundED UpDATE regional meeting, made possible by a grant from PCCA. Also, Topi-CLICK is sponsoring an APC ‘Compounder Get-Together” in Boston on the evening of June 18.
We’re less than six weeks from EduCon 2024, APC’s hot-topics-and-best-practice webinar series for compounding pharmacists and technicians.
Why? Because the current misinformation about compounding – particularly compounded GLP-1s – is a hairball that the media can’t seem to cough up.
FOLLOW US
